191 related articles for article (PubMed ID: 32584959)
1. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
Kim H; Jeong H; Yamaguchi M; Sohn I; Yoon SE; Byeon S; Hur JY; Koh Y; Yoon SS; Kim EJ; Oguchi M; Miyazaki K; Taguchi S; Yoon DH; Cho J; Ko YH; Kim SJ; Suzuki R; Kim WS
Blood; 2020 Nov; 136(22):2548-2556. PubMed ID: 32584959
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
3. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
[TBL] [Abstract][Full Text] [Related]
4. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
Kim SJ; Oh SY; Hong JY; Chang MH; Lee DH; Huh J; Ko YH; Ahn YC; Kim HJ; Suh C; Kim K; Kim WS
Ann Oncol; 2010 May; 21(5):1058-63. PubMed ID: 19850636
[TBL] [Abstract][Full Text] [Related]
5. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.
Kang S; Cho H; Kim S; Lee K; Kang EH; Park JS; Lee YS; Park CS; Go H; Huh J; Ryu JS; Lee SW; Kim SJ; Kim WS; Yoon SE; Ko YH; Suh C
Cancer Res Treat; 2023 Jan; 55(1):314-324. PubMed ID: 35381163
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
7. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
8. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
9. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
11. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
Li X; Yu H; Fu X; Zhang L; Li X; Li L; Wang X; Sun Z; Zhang X; Li Z; Wu J; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Hematol Oncol; 2023 Apr; 41(2):267-274. PubMed ID: 34061378
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Lewis KL; Jakobsen LH; Villa D; Smedby KE; Savage KJ; Eyre TA; Cwynarski K; Bishton MJ; Fox CP; Hawkes EA; Maurer MJ; El-Galaly TC; Cheah CY;
J Clin Oncol; 2023 Dec; 41(35):5376-5387. PubMed ID: 37797284
[TBL] [Abstract][Full Text] [Related]
13. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
Lee K; Yoon DH; Hong JY; Kim S; Lee K; Kang EH; Huh J; Park CS; Lee SW; Suh C
Int J Hematol; 2019 Jul; 110(1):86-94. PubMed ID: 31115880
[TBL] [Abstract][Full Text] [Related]
14. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
[TBL] [Abstract][Full Text] [Related]
15. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of prognostic nutritional index on extranodal natural killer/T-cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working Group.
Shen Z; Zhang S; Chen X; Zhang Q; Jiao Y; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Wang L; Cai G; Sang W
Hematol Oncol; 2023 Aug; 41(3):380-388. PubMed ID: 36680513
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
18. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
19. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
20. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
